Source brief: A systematic review of the effect of semaglutide on lean mass

What this source says

Review context for interpreting lean-mass changes during semaglutide-supported weight loss.

Why it matters

This source is part of LHN's longevity drugs evidence trail. Reading the original helps separate what the source actually addresses from broader online claims.

What it does not prove

Lean mass is not identical to contractile muscle, and body-composition findings do not create a personal treatment plan.

How LHN is using it

This brief records the source in the public evidence trail and links to the original. It does not turn a paper, registry entry or regulatory document into personal medical advice. The source's design, population and stated limitations still determine what conclusions are reasonable.

Read the original source

Lean mass is not identical to contractile muscle, and body-composition findings do not create a personal treatment plan.

Open Journal of Cachexia, Sarcopenia and Muscle

Read next

do glp 1s cause muscle lossstart hereclaimslongevity drugswhat is rapamycin

Get the weekly longevity evidence briefing.

One plain-English email on the claims, studies and regulatory updates worth knowing - without protocols, hype or miracle claims.

No protocols. No miracle claims. No spam.

NameEmailLeave this empty

Choose your interests

I'm new to longevityPeptides and regulationRapamycin and longevity drugsNAD and supplementsGene therapy frontierBiological age and testing

Get the weekly briefingI agree to receive the weekly evidence briefing and understand I can unsubscribe. Do not send personal medical information. See privacy.